Generic Fosamax Users Must Give More Details In MDL

Law360, New York (December 19, 2013, 8:04 PM EST) -- A New York federal judge on Wednesday ordered plaintiffs in multidistrict litigation against Teva Pharmaceuticals USA Inc. to divulge when they had taken a generic version of the bone drug Fosamax, in order to back the claim that Teva's failure to update the drug's labeling had led to their jaw injuries.

The ruling came in response to Teva's motion for a more definite statement following U.S. District Judge John Keenan's August decision that all of the claims against Teva were preempted except so-called failure-to-update allegations....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.